Pfizer Stock: It's Time To Buy The Dip
Pfizer's depressed valuation and strong product pipeline make it the ultimate buying opportunity for income investors in the healthcare sector. Despite a decline in sales of COVID-19 drugs, Pfizer'...
Pfizer Is A Great Investment Over The Next Decade; Buy
Pfizer Is A Great Investment Over The Next Decade; Buy
Pfizer might get Alzheimer's lift from Viagra, study suggests
Pfizer had some rare good news in a tough twelve months for the US pharma as a new study suggested that men who take Viagra for erectile dysfunction might have a reduced risk of Alzheimer's disease...
Pfizer's Problems Go Far Beyond Just Declining COVID Revenue
Can Pfizer's stock bounce back? Pfizer's revenue crashed last quarter and it posted a massive $3.4 billion net loss. Problem is that many of the company's top products are generating little or no g...
Pfizer: The 6.3% Yield Is A Appealing
Pfizer reported better than expected Q4 earnings, with solid organic top line growth in FY 2023, despite a drop in COVID-19 product revenues. The drop-off in COVID-19 product sales has caused negat...
Pfizer: Simply Too Cheap To Ignore
Pfizer reported a record $100 billion in annual revenue in 2022 due to the development of Comirnaty and Paxlovid. COVID treatments no longer boost sales, causing the stock to trade near a ten-year ...
Pfizer's 2024 Comeback: A Dividend Gem in the Pharma Market
Interestingly, there are no Big Pharma companies listed in the “Magnificent Seven.” Consequently, perfectly good companies like Pfizer (NYSE: PFE ) are being overlooked, but that's not bad news at ...
Is the Worst Over for Pfizer?
Pfizer's revenue is on the decline after reaching a record high back in 2022. However, the pharma giant is counting on new product approvals and business deals to spur a new phase of growth.
Pfizer Is Down 54% From Highs, Now Yields 6.1%
Pfizer Inc. stock has experienced a significant decline from its all-time high to the lowest price in over 10 years. Despite lower sales from its COVID-19 vaccines, Pfizer's other revenues grew 7% ...
Pfizer CEO doubles down on 2024 guidance, talks Seagen buy
Pfizer (PFE) reported fourth-quarter earnings on Tuesday morning that beat. Wall Street expectations.
Pfizer Inc. (PFE) Q4 2023 Earnings Call Transcript
Pfizer Inc. (PFE) Q4 2023 Earnings Call Transcript
How Pfizer (PFE) Can Succeed In A Post-Pandemic World
Pfizer's (PFE) 4Q adjusted EPS came in at $0.10 versus an estimated -$0.19 and revenue came in at $14.25B versus an estimated $14.36B. Lee Bohl and Sel Hardy discuss the takeaways from Pfizer's ear...
Why Pfizer Stock Was Jumping Today, but Then Gave Up Its Gains
Pfizer reported better-than-expected revenue and adjusted earnings for the fourth quarter. This news spurred a jump for the pharma stock.
Pfizer (PFE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compa...
Pfizer (PFE) Q4 Earnings Top, Revenues Miss on COVID Sales Slump
Pfizer (PFE) reports mixed fourth-quarter 2023 results. It re-affirms its 2024 sales and earnings guidance provided in December 2023.
Related Companies